

# ***Marc Miravittles – The role of ICS in COPD treatment***

## **Select podcast references**

- Bakeer M, et al. *Ann Transl Med* 2020;8:1472 (Phenotypes in COPD)
- Brusselle G, et al. *Int J Chron Obstruct Pulmon Dis* 2015;10:2207–2217 (Real world evidence of ICS use)
- Cazzola M, et al. *Eur Respir J* 2018;52:1801586 (LAMA/LABA vs. triple therapy)
- Chalmers JD, et al. *Eur Respir J* 2020;55:2000351 (European Respiratory Society Guidelines)
- Couturaud F, et al. *JAMA* 2021;325:59-68 (Prevalence of pulmonary embolism)
- Ferguson GT, et al. *Lancet Respir Med* 2018;6:747–758 (LAMA/LABA vs. triple therapy)
- Global Initiative for Chronic Obstructive Lung Disease. Updated 2021 (GOLD 2021 Strategy)
- Horita N, et al. *Cochrane Database Syst Rev* 2017;2:CD012066 (LAMA/LABA vs. LABA/ICS)
- Lipson DA, et al. *N Engl J Med* 2018;378:1671–1680 (LAMA/LABA vs. triple therapy)
- Price D, et al. *Prim Care Respir J* 2013;22:92–100 (Risk to benefit ratio of ICS)
- Stolz D & Miravittles M. *Eur Respir J* 2020;55:2000881 (Withdrawal of ICS)